SCHEMBL6045308

SCHEMBL6045308

OCCC1CNCCN1CCCCN1c2ccccc2Oc2ccc(Cl)cc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.56
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
HDAC3 O15379 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
HDAC4 P56524 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
HDAC1 Q13547 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045312 0.98 PIM1 (0.56) PIM1KMT2AMEN1TDP1HDAC3
SCHEMBL6045244 0.91 PIM1 (0.41) PIM1KMT2AMEN1TDP1HDAC3
SCHEMBL6045358 0.80 PIM1 (0.43) PIM1KMT2AMEN1ALDH1A1TP53
SCHEMBL13305308 0.76 PIM1 (0.65) PIM1KMT2AMEN1TDP1HDAC3
SCHEMBL5082472 0.76 CYP2D6 (0.61) PIM1KMT2AMEN1TDP1USP2
Hydrochloric Acid SCHEMBL3441267 0.75 CYP2D6 (0.60) PIM1KMT2AMEN1TDP1USP2
SCHEMBL23352468 0.73 PIM1 (0.61) PIM1KMT2AMEN1TDP1HDAC3
SCHEMBL9419643 0.72 CA1 (0.40) ALDH1A1CACNA1B
SCHEMBL29444947 0.71 MEN1 (0.71) PIM1KMT2AMEN1TDP1HDAC3
SCHEMBL6104044 0.70 PIM1 (0.60) PIM1KMT2AMEN1TDP1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060241108-A1 Substituted phenoxazines and acridones as inhibitors of AKT ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2006-10-26 US claimed
WO-2006094207-A2 SUBSTITUTED PHENOXAZINES AND ACRIDONES AS INHIBITORS OF AKT ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2006-09-08 WO claimed
US-20060241108-A1 Substituted phenoxazines and acridones as inhibitors of AKT ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2006-10-26 US disclosed
WO-2006094207-A2 SUBSTITUTED PHENOXAZINES AND ACRIDONES AS INHIBITORS OF AKT ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241108-A1 Substituted phenoxazines and acridones as inhibitors of AKT AKT1S1, AKT3, PIK3CA PIM1 572/4885KMT2A 1181/4885MEN1 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.